Skip to main content
An official website of the United States government
Government Funding Lapse

Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

Program Official
Principal Investigator
Charles Drescher
Awardee Organization

Swedish Medical Center, First Hill
United States

Fiscal Year
2025
Activity Code
UG1
Early Stage Investigator Grants (ESI)
Not Applicable
Project End Date

The Pacific Cancer Research Consortium (PCRC), an NCORP Community Site

In 2013, the Pacific Cancer Research Consortium (PCRC) was created to bring clinical trials and cancer care delivery research to community cancer treatment centers in the Western United States as an NCI Community Oncology Research Program (NCORP) Community Site. Under a multiple PI/PD structure, the 3 primary component sites—Swedish Cancer Institute in Seattle, Providence Portland Medical Center in Portland, and St. Luke’s Cancer Institute in Boise—have facilitated the conduct of NCORP-sponsored trials at more than 40 affiliate sites in Alaska, Washington, Oregon, Idaho, Montana, and California. Over the past 12 years, the PCRC built on its collective experience in clinical research, its shared organizational structure, and its community demographics to deliver accessible research trials, enhance community engagement in research, and provide quality cancer care. As an established NCORP Community Site, the PCRC will continue to “bring cancer clinical research studies to individuals in their own communities” by (1) conducting clinically important treatment trials that include robust accrual strategies and fair access for everyone, (2) participating in cancer control and prevention studies, cancer care delivery research, and screening, and imaging trials proposed by the NCORP Research Bases, (3) optimizing and streamlining procedures to ensure timely and accurate data submission and specimen collection, (4) enhancing visibility, recruitment, participation, education, and broad population engagement including patient advocates in NCORP activities, and (5) mentoring the next generation of community-based cancer clinical trialists.

Publications

  • Haas NB, Manola J, Uzzo RG, Flaherty KT, Wood CG, Kane C, Jewett M, Dutcher JP, Atkins MB, Pins M, Wilding G, Cella D, Wagner L, Matin S, Kuzel TM, Sexton WJ, Wong YN, Choueiri TK, Pili R, Puzanov I, Kohli M, Stadler W, Carducci M, Coomes R, DiPaola RS. Adjuvant sunitinib or sorafenib for high-risk, non-metastatic renal-cell carcinoma (ECOG-ACRIN E2805): a double-blind, placebo-controlled, randomised, phase 3 trial. Lancet (London, England). 2016 May 14;387(10032):2008-16. Epub 2016 Mar 9. PMID: 26969090
  • Khan SA, Zhao F, Goldstein LJ, Cella D, Basik M, Golshan M, Julian TB, Pockaj BA, Lee CA, Razaq W, Sparano JA, Babiera GV, Dy IA, Jain S, Silverman P, Fisher CS, Tevaarwerk AJ, Wagner LI, Sledge GW. Early Local Therapy for the Primary Site in De Novo Stage IV Breast Cancer: Results of a Randomized Clinical Trial (EA2108). Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2022 Mar 20;40(9):978-987. Epub 2022 Jan 7. PMID: 34995128
  • McLouth LE, Zheng Y, Smith S, Hodi FS, Rao UN, Cohen GI, Amatruda TT, Dakhil SR, Curti BD, Nakhoul I, Chandana SR, Bane CL, Marinier DE, Lee SJ, Sondak VK, Kirkwood JM, Tarhini AA, Wagner LI. Patient-reported tolerability of adjuvant ipilimumab (3 or 10 mg/kg) versus high-dose interferon alfa-2b for resected high-risk stage III-IV melanoma in phase III trial E1609. Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation. 2023 Jan;32(1):183-196. Epub 2022 Aug 27. PMID: 36029412